LEO 39652

Drug Profile

LEO 39652

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator LEO Pharma
  • Class Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Atopic dermatitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Atopic-dermatitis in United Kingdom (Topical, Cream)
  • 01 Jan 2015 LEO Pharma completes a phase I trial in Atopic dermatitis in Germany (NCT02219633)
  • 01 Dec 2014 LEO Pharma completes a phase I trial in Atopic dermatitis and Healthy volunteers in United Kingdom (NCT01850849)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top